Clinical Practice Guidelines for the management of locally advanced ...

More documents

Recommendations

Info

and chemotherapy 89–90 see also bone pain palliative care 96–97, 100–101 and decision making 98 end-of-life care 99–100 evidence summaries 101, 102 interdisciplinary 97 literature searches on 97–98 recommendations 101–102 referrals 97, 101 and symptoms 98–99 Palliative Care ACT 143 Palliative Care Australia 96 Palliative Care Council of NSW 143 Palliative Care Council of South Australia 143 Palliative Care NT 143 Palliative Care Queensland 143 palliative care services 98, 99–100 Palliative Care Victoria 143 Palliative Care WA 143 pamidronate disodium 80–81 partial remission 139 partners of men with prostate cancer 3 interventions to alleviate distress 10 and sexual function 9 pathologic T3/T4 disease post radical surgery 34–36 evidence summaries 36 recommendations 36 pathological classification 130 PC-SPECS (herbal conglomerate) 106 peer support 3, 5–6 pelvic imaging 75 pelvis 139 physical activity 7–9, 99 pituitary 136 pomegranate seeds extracts 106 prednisolone 88–90 primary tumours 139 classification of 129 prognosis 3–4, 132, 139 progression 75 prostate, biopsy of 135 prostate cancer, incidence 1–2 Prostate Cancer Clinical Trials Working Group 75 Prostate Cancer Foundation of Australia 3, 117, 143 resources 12 Prostate Cancer Support Groups 143 prostate enlargement, benign 135 prostate specific antigen (PSA) 139 castration-resistant prostate cancer 75, 88 and diagnosis 1 rise following definitive local therapy 48 prostate tumours, classification of 129–132 prostatectomy 31–32, 139 and androgen deprivation therapy(ADT) 32–34 and radiotherapy 34–36 157 Index
ise in prostate specific antigen (PSA) following 48 prostatic hyperplasia, benign 135 proststitis 139 protocol 139 PSA see prostate specific antigen (PSA) psychology, interventions to improve 5–7 psychosocial 140 psychosocial care 3 depression and anxiety 10–12 diet and lifestyle interventions 7–9 evidence summaries 4, 7, 8, 9, 10, 11 interventions to alleviate partner distress 10 interventions to improve knowledge 3–4 psychological and cognitive interventions 5–7 recommendations 4, 7, 9, 10, 11 sexual functioning interventions 9 quality of life (QOL) 140 and androgen deprivation therapy (ADT) 23–24, 56–57 and chemotherapy 89–90 interventions to improve 7–9 and palliative care 98 and radioisotopes 86 race 111 radiation oncologist 140 radioisotopes 84–88 and bone pain 84–85 emerging therapies 116 evidence summaries 85, 86, 87 and quality of life (QOL) 86 recommendations 85, 86, 88 side effects 87–88 and survival 85–86 radiotherapy 140 biochemical relapse 115 and bone pain 59–61 fatigue after 7–9 hemibody external beam 65–66 locally advanced disease 24–28, 115 and androgen deprivation therapy (ADT) 29–31, 36–38 evidence summaries 26, 27, 29, 31, 36, 37, 38 node-positive disease 36–38 pathologic T3/T4 disease post radical surgery 34–36 recommendations 26, 27, 28, 30, 31, 36, 37, 38 toxicity 30–31 loco-regionally progressive disease 61–62 metastatic disease bone pain 59–61 evidence summaries 61, 62, 63, 64, 65, 66 hemibody external beam 65–6 loco-regionally progressive disease 61–62 recommendations 61, 62, 63, 64, 65 spinal cord compression 62–65 palliative 99 radioisotopes 84–88 rise in prostate specific antigen (PSA) following 48 salvage 48 Clinical practice guidelines for the management of locally advanced and metastatic prostate cancer 158
Page 1:
Clinical Practice Guidelines for th
Page 4 and 5:
4 Biochemical relapse .............
Page 6 and 7:
FOREWORD The management of prostate
Page 8 and 9:
SUMMARY OF CLINICAL PRACTICE RECOMM
Page 10 and 11:
SUMMARY OF RECOMMENDATIONS Chapter
Page 12 and 13:
Chapter Recommendations Grade Refs
Page 14 and 15:
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
1 INTRODUCTION 1.1 Natural history
Page 22 and 23:
2 PSYCHOSOCIAL CARE The diagnosis a
Page 24 and 25:
2.2 Effect of psychological and cog
Page 26 and 27:
Evidence summary Level References T
Page 28 and 29:
Recommendation Men with advanced pr
Page 30 and 31:
An Australian cross-sectional study
Page 32 and 33:
10. Dunn J, et al. A review of peer
Page 34 and 35:
41. Sharpley CF, Christie DRH. An a
Page 36 and 37:
different treatments from different
Page 38 and 39:
Evidence summary Level References I
Page 40 and 41:
Evidence summary Level References F
Page 42 and 43:
Despite these reservations and the
Page 44 and 45:
For non-metastatic disease there we
Page 46 and 47:
Evidence summary Level References T
Page 48 and 49:
monotherapy for low-to-intermediate
Page 50 and 51:
Evidence summary Level References M
Page 52 and 53:
for surgery, suggesting that surger
Page 54 and 55:
Microscopic fully resected node pos
Page 56 and 57:
All three trials demonstrated impro
Page 58 and 59:
Evidence summary Level References B
Page 60 and 61:
of an international multicentre ran
Page 62 and 63:
45. Melton LJ, III, Alothman KI, Kh
Page 64 and 65:
76. Little DJ, Kuban DA, Levy LB, Z
Page 66 and 67:
105. Thompson IM, Tangen CM, Parade
Page 68 and 69:
4.2 Androgen deprivation therapy (e
Page 70 and 71:
Evidence summary Level References F
Page 72 and 73:
therapy since such studies would be
Page 74 and 75:
apparent in trials comparing CAB wi
Page 76 and 77:
QLQ instrument published by Cleary
Page 78 and 79:
Note: Larger well-powered studies h
Page 80 and 81:
Eight trials examined acute toxicit
Page 82 and 83:
half of patients experienced pain r
Page 84 and 85:
olus) in addition to radiotherapy a
Page 86 and 87:
References 1. Seidenfeld J, Samson
Page 88 and 89:
Cooperative Group. Scandinavian Jou
Page 90 and 91:
Oncology Group, TROG 96.05). Radiot
Page 92 and 93:
trial. European Journal of Cancer 1
Page 94 and 95:
6 CASTRATION-RESISTANT PROSTATE CAN
Page 96 and 97:
the median overall survival for pat
Page 98 and 99:
There are two points regarding bisp
Page 100 and 101:
with bone pain at study entry. At n
Page 102 and 103:
Recently, there have been reports o
Page 104 and 105:
of these studies 56, 58 and in the
Page 106 and 107:
Side effects (toxicity) As these ra
Page 108 and 109:
hydrocortisone respectively. Tannoc
Page 110 and 111:
5. Manikandan R, Srirangam SJ, Pear
Page 112 and 113:
33. Elomaa I, Kylmala T, Tammela T
Page 114 and 115:
60. Janknegt RA, Abbou CC, Bartolet
Page 116 and 117:
physiotherapists, occupational ther
Page 118 and 119:
7.5 Q2: Symptom control There was e
Page 120 and 121:
Informal or family caregivers deriv
Page 122 and 123:
8. Hughes SL, Weaver FM, Giobbie-Hu
Page 124 and 125:
8 COMPLEMENTARY AND ALTERNATIVE (UN
Page 126 and 127: corresponding benefit in obstructiv
Page 128 and 129: 3. Eisenberg DM, Kessler RC, Van Ro
Page 130 and 131: areas of the state were more likely
Page 132 and 133: 8 Miller DC, Litwin MS, Bergman J,
Page 134 and 135: 10 EMERGING THERAPIES It is impossi
Page 136 and 137: APPENDIX 1 GUIDELINE DEVELOPMENT PR
Page 138 and 139: study type. Studies published befor
Page 140 and 141: Grade of recommendation Description
Page 142 and 143: 2. National Health and Research Cou
Page 144 and 145: Dr Carole Pinnock AM Principal rese
Page 146 and 147: Surgery Professor Villis Marshall A
Page 148 and 149: APPENDIX 3 TNM CLASSIFICATION OF PR
Page 150 and 151: Summary Prostate T1 T2 T3 T4 N1 M1a
Page 152 and 153: APPENDIX 4 ABBREVIATIONS AND GLOSSA
Page 154 and 155: Glossary Actuarial survival A metho
Page 156 and 157: Effectiveness The extent to which a
Page 158 and 159: Lymph nodes Small, generally pea-si
Page 160 and 161: Each stage is divided into subgroup
Page 162 and 163: APPENDIX 6 - ORGANISATIONS WHICH PR
Page 164 and 165: Consultant Urologist, Royal Brisban
Page 166 and 167: No conflict of interest to declare.
Page 168 and 169: Index to Clinical practice guidelin
Page 170 and 171: cardiovascular mortality 19, 54, 55
Page 172 and 173: androgen deprivation therapy (ADT)
Page 174 and 175: and surgery 32-34 survival 18 toxic
Page 178 and 179: spinal cord compression 62-63 see a
Page 180 and 181: systemic 141 Tasmania Association f
show all

Clinical Practice Guidelines for the management of locally advanced ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?